Company intelligence / Profile preview

SMIVET BV

Ownership: Private
Development stage: Commercial

Overview

SMIVET BV has developed proprietary single-domain antibody libraries and a supportive SDA platform aimed at creating innovative biotherapeutic solutions for a range of animal species. The company collaborates with academic and industry specialists to advance its research pipeline. No specific clinical results are disclosed as of the latest available information[1].

Therapeutic areas: OtherInfectious Diseases
Modalities: Single Domain Antibodies (SDAs)NanobodiesBiotherapeutics for animals
Industry: Veterinary

Drug pipeline

2 assets

RL490

Commercial

Indications: Tetanus

1 more asset in the full pipeline.

Request access →

Partnerships

Laboratorios Syva S.A. (strategic partnership announced March 2023)[1]

Beyond the preview

Go deeper on SMIVET BV.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SMIVET BV.

Explore the full profile